Navigation Links
Britains Complacent Attitude To Uptake Of New Cancer Drugs Revealed

Swedish scientists have come out with the report that with UK leading the group, cancer patients face "stark inequalities" in access to treatment including the use of new drugs.

The study termed uptake of new cancer drugs as "low and slow" in the UK, as well as in New Zealand, Poland, Czech Republic and South Africa. On the other hand, Austria, France, Switzerland and the US were leaders in using new cancer drugs.

The study, published in cancer journal Annals of Oncology, was documented by Dr Nils Wilking, clinical oncologist at the Karolinska Institute in Stockholm, Sweden, and Dr Bengt Jonsson, director of the Centre for Health Economics at the Stockholm School of Economics.

The researchers surveyed Australia, Canada, New Zealand, Japan, South Africa and the US, as well as 19 European countries, with a total population of 984 million, and looking at access to 67 innovative cancer drugs.

They found differences in access reflected in patient outcome, in five major western European countries - France, Germany, Italy, Spain and the UK.

France had the highest five-year survival rate for all cancers apart from non-melanoma skin cancer - 71% for women and 53% for men. The UK had the lowest at 53% and 43% respectively. In France, Spain, Germany and Italy, 51-52% of cancer patients were treated with drugs launched after 1985. But only 40% of patients in the UK had access to these drugs.

Says Dr Jonsson: "Around one sixth of the differences between these five countries in five-year cancer survival are due to differences in the uptake of new drugs in each country." In addition, the report stresses an imbalance in public investments in cancer research between Europe and the US.

"Not only is the magnitude of public research at a different level in the United States, it is also directed to clinical research to a greater extent. There is a need for a significant increase in the public resear ch for cancer in Europe particularly devoted to clinical research, Jonsson was quoted.

Generally, the greatest differences in uptake were noted for the new colorectal and lung cancer drugs, which are among the world's top cancer killers for both men and women. The US uptake of bevacizumab for colorectal cancer was 10 times the uptake of the European average, with the UK having a very low uptake.

Dr Jonsson concluded: "We believe that the inequalities between countries in patients' access to cancer drugs cannot persist. Cancer patients will not accept that a standard of care available in one country is not available in other countries."

Recommendations from the report include reducing the review time for the marketing authorization of new cancer drugs and ensuring that, once this is obtained, the drug is available without further delays.

A Department of Health spokesman was quoted: "We are making good progress in ensuring cancer patients have access to the drugs they need. A report published by the national cancer director last year confirmed a continued increase in the uptake of new cancer drugs by the NHS following positive Nice appraisal. "It also confirmed a reduction in the variation of use of these drugs around the country. We have reiterated in recent guidance that NHS should not withhold funding for treatments just because Nice guidance is not available."


'"/>




Related medicine news :

1. Shocking Figures Of Britains Abused Elders Revealed
2. Attitude affects lifes quality
3. Our Attitude To Food Costing Us A Fortune
4. Attitude Towards AIDS Patients – Time For A Change
5. Attitude Of Male Dominance May Affect Life Expectancy In Men
6. Adolescents Influenced By Maternal Attitude Regarding Weight Control
7. Madhya Pradesh Shows Indifferent Attitude Towards Infant Mortality
8. Risk Attitudes And Consequences Of College Drinking
9. Mother’s Attitude Towards Immunisation Makes it Inaccessible to Childre
10. Coffee Stimulants Could Make us to Change The Attitude
11. Attitudes About Aging Different from Reality
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... , ... April 24, 2017 , ... ... within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick ... Available 24 hours a day, Quick Care provides patients with the option to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on ... Blvd, for an educational and exciting 2-day program. , An attendee at a ... before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
Breaking Medicine Technology: